Zafgen Inc. (Nasdaq: ZFGN) disclosed that a patient in an ongoing Phase 3
study of its Prader-Willi Syndrome treatment beloranib died. The stock
price surged $3.75 to close at $19.50 after two days of uncertainty when the company cancelled
investor meetings.
Zafgen addresses concerns
October 14, 2015 at 18:19 PM EDT
